Searched for
ISB 2001
Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...- Glenmark Q3 profit rises 16% on strong India, US performanceGlenmark Pharmaceuticals posted 16% growth in December-quarter profit on strong India formulations demand, improved North America performan...
- Glenmark shares gain 2% as firm receives $700 million upfront payment from AbbVie dealGlenmark Pharmaceuticals' shares surged following its subsidiary's $700 million upfront payment from AbbVie for an exclusive licensing agre...
- Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugsGlenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio a...
- Glenmark Pharma shares rally 14% on AbbVie boost; analysts hike targets to Rs 2,800Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug, ISB 2001...
- Glenmark Pharmaceuticals shares rally up to 20%, mutual funds lead the charge over retail investorsThe shares of Glenmark Pharmaceuticals surged 20% on Friday, July 11, to a day’s high of Rs 2,286 following a landmark $2 billion licensing...
- Motilal Oswal sees 28% upside in Glenmark Pharma, hails $700 mln cancer drug deal as ‘new era’ for innovation playGlenmark Pharma shares: The brokerage noted that the agreement—executed through Glenmark’s subsidiary, Ichnos Glenmark Innovation (IGI)—“va...
- Glenmark Pharma hits 10% upper circuit, scales fresh 52-week high on $700 mn cancer drug dealGlenmark Pharma Share Price: Glenmark Pharmaceuticals' shares soared after its subsidiary, Ichnos Glenmark Innovation, inked a global licen...
- Glenmark, AbbVie ink $700 million drug licensing dealGlenmark Pharmaceuticals has entered into a significant agreement with AbbVie to commercialize its investigational drug, ISB 2001, targetin...
- Glenmark’s blood cancer drug ISB 2001 shows promising results in trialIchnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating...
- Glenmark Pharma shares up 2% after FDA grants fast track status to cancer drugGlenmark Pharma's innovation arm, IGI, received FDA fast track designation for its myeloma therapy ISB 2001, targeting heavily pre-treated ...
- US prospects, new drugs make Glenmark look betterGlenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 appli...
- Rajendra Srivastava of SMU to be new dean of Indian School of BusinessThe next dean of the Indian School of Business will be Rajendra Srivastava, 64, provost and deputy president of academic affairs at Singapo...
- ISB exec board meets tomorrow; likely to choose new chairmanThe executive board of Indian School of Business which will meet tomorrow in Hyderabad is likely to appoint a new Chairman, after the biz s...
- MIT Sloan collaborating with ISB HyderabadMIT Sloan is heading up for a new collaboration with Business schools in India, by entering into a partnership with Indian School of Busine...
- Three new directors to join ISB boardHyderabad-based Indian School of Business appointed three new directors to join the existing near thirty-member board, the dean of the inst...
- ISB moves up to 15th in top-100 B-school listFor the second year in a row, Indian School of Business, Hyderabad has been the only Indian management institute that has made it to the Fi...
- ISB to launch second campus in MohaliThe country's leading business school, the Indian School of Business (ISB), is setting up another campus at Mohali in Punjab in an agreemen...
- North to get its own ISB, courtesy four biz honchosFour leading Delhi-based industrialists-Sunil Mittal, BM Munjal, Analjit Singh and Atul Punj have joined hands to bring the ISB to the nort...
- ISB not knowtowing before regulatorTop B-School snubs regulator, lobbying for accreditation from US panel.
Load More
